# CRCM LP

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1483234. Source: https://holderbook.com/funds/1483234-crcm-lp/

- Reported value: $448.3M
- Positions: 14
- Weight of the ten largest: 98.8%
- Filed: 2026-08-12

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| ISHARES GOLD TR | [IAU](https://holderbook.com/stocks/IAU/) | $296.8M | 3,929,963 | 66.2% | 10 |
| ISHARES BITCOIN TRUST ETF | [IBIT](https://holderbook.com/stocks/IBIT/) | $30.3M | 910,665 | 6.8% | 1 |
| ATRIUM THERAPEUTICS INC | [RNA](https://holderbook.com/stocks/RNA/) | $25.1M | 1,866,333 | 5.6% | 1 |
| AI FINL CORP | [AIFC](https://holderbook.com/stocks/AIFC/) | $22.3M | 38,104,590 | 5.0% | 4 |
| BITGO HOLDINGS INC | [BTGO](https://holderbook.com/stocks/BTGO/) | $20.4M | 3,936,513 | 4.5% | 1 |
| PLAYBOY INC | [PLBY](https://holderbook.com/stocks/PLBY/) | $15.0M | 12,280,439 | 3.3% | 7 |
| ISHARES TR | [SGOV](https://holderbook.com/stocks/SGOV/) | $14.3M | 141,723 | 3.2% | 1 |
| VIZSLA SILVER CORP | [VZLA](https://holderbook.com/stocks/VZLA/) | $8.4M | 2,544,648 | 1.9% | 1 |
| BURNING ROCK BIOTECH LTD | [BNR](https://holderbook.com/stocks/BNR/) | $5.3M | 635,991 | 1.2% | 7 |
| PROCAP ACQUISITION CORP | [PCAP](https://holderbook.com/stocks/PCAP/) | $5.0M | 481,968 | 1.1% | 4 |
| PERCEPTIVE CAP SOLUTIONS COR | [PCSC](https://holderbook.com/stocks/PCSC/) | $3.2M | 291,795 | 0.7% | 3 |
| FIRST TRACKS BIOTHERAPEUTICS | [TRAX](https://holderbook.com/stocks/TRAX/) | $2.1M | 106,020 | 0.5% | 1 |
| USBC INC. | [USBC](https://holderbook.com/stocks/USBC/) | $173.8K | 555,325 | 0.0% | 4 |
| PROCAP ACQUISITION CORP | [PCAPW](https://holderbook.com/stocks/PCAPW/) | $32.9K | 102,735 | 0.0% | 1 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | -17.8% | +14.8% | -32.6% | 99% |
| Q1 2026 | -17.1% | -4.6% | -12.5% | 95% |
| Q4 2025 | +4.2% | +2.4% | +1.8% | 100% |
| Q3 2025 | +14.0% | +7.8% | +6.2% | 100% |
| Q2 2025 | +57.5% | +10.5% | +47.0% | 100% |
| Q1 2025 | +0.5% | -4.6% | +5.0% | 100% |
| Q3 2024 | +6.0% | +5.4% | +0.5% | 100% |
| Q2 2024 | -10.1% | +4.0% | -14.1% | 100% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $448.3M | 14 |
| Q1 2026 | $141.2M | 8 |
| Q4 2025 | $296.0M | 11 |
| Q3 2025 | $345.7M | 10 |
| Q2 2025 | $336.6M | 9 |
| Q1 2025 | $245.3M | 6 |
| Q4 2024 | $245.9M | 6 |
| Q3 2024 | $154.5M | 4 |
| Q2 2024 | $138.3M | 6 |
| Q1 2024 | $132.9M | 6 |